Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Dec;95(12):E338-E339.
doi: 10.1002/ajh.26002. Epub 2020 Sep 30.

Severe infusion-related reaction to crizanlizumab in an adolescent with sickle cell disease

Kristine Karkoska  1 , Charles T Quinn  1   2 , Kelly Clapp  1 , Patrick T McGann  1   2
Affiliations
Free article
Clinical Trial

Severe infusion-related reaction to crizanlizumab in an adolescent with sickle cell disease

Kristine Karkoska et al. Am J Hematol. 2020 Dec.
Free article
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Matsui NM, Borsig L, Rosen SD, Yaghmai M, Varki A, Embury SH. P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. Blood. 2001;98:1955-1962.
    1. Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci U S A. 2002;99:3047-3051.
    1. Gutsaeva DR, Parkerson JB, Yerigenahally SD, et al. Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. Blood. 2011;117:727-735.
    1. Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376:429-439.
    1. Kutlar A, Kanter J, Liles DK, et al. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: a SUSTAIN study analysis. Am J Hematol. 2019;94(1):55-61.

Substances

LinkOut - more resources